Agenus | AGEN - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 740M 40M 2025-06
Agenus USD 16.02M 2.85M 2025-12
Amgen USD 653M 32M 2025-12
AstraZeneca USD 484M 181M 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
CSL USD 215M 111M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 188M 21M 2025-12
Glaxosmithkline GBP 177.95M 6.05M 2025-09
Incyte USD 582K 10K 2025-12
Intrexon USD 2K 5K 2024-06
J&J USD 18M 290M 2025-09
Jiangsu Hengrui CNY 254.59M 253.85M 2025-09
Karyopharm Therapeutics USD 11.38M 2.43M 2024-09
MacroGenics USD 3.34M 2.54M 2025-09
Merck EUR 121M 5M 2025-12
Merck USD 412M 85M 2025-12
Northwest Biotherapeutics USD 1.52M 276K 2024-03
Novartis USD 304M 23M 2025-12
Novavax USD 5.82M 342K 2025-12
Pfizer USD 711M 59M 2025-12
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sangamo BioSciences 97.56M 11.39M 2025-06
Veracyte USD 2K 1000 2023-12